Pharma BD Deal Intelligence
Sanofi paid up to $2.2B for Inhibrx to acquire INBRX-101, a recombinant AAT-Fc fusion for alpha-1 antitrypsin deficiency. The deal targeted a rare lung disease currently treated only with plasma-derived augmentation—betting a next-generation recombinant approach could capture a $2B+ market.
Sanofi acquired Inhibrx for up to $2.2B for AATD treatment.
Sanofi completes acquisition of Inhibrx, Inc. (closed 2024-05-30); non-101 assets spun out into Inhibrx Biosciences, Inc.
Sanofi: efdoralprin alfa (SAR447537, formerly INBRX-101) met all primary and key secondary endpoints in the ElevAATe Phase 2 study in AATD emphysema;…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sanofi acquired Inhibrx for up to $2.2B for AATD treatment.
6K US cases/yr · $2.0B Global AATD Market (2024)
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disorder caused by SERPINA1 variants (most commonly PiZZ) that reduce circulating functional alpha-1 antitrypsin. AATD affects roughly 1 in 1,500 to 3,500 individuals of European ancestry and is substantially underdiagnosed. Clinical manifestations include early-onset panacinar emphysema (often by age 25-50, accelerated by smoking), liver disease ranging from neonatal cholestasis to adult cirrhosis and hepatocellular carcinoma, and rare panniculitis. Standard of care for lung disease is IV plasma-derived AAT augmentation therapy.
Current: weekly IV plasma-derived AAT (Prolastin-C, Aralast, Zemaira). Efdoralprin alfa offers longer dosing interval and potentially superior functional protein levels.
Sanofi completed up to $2.2B acquisition of Inhibrx, gaining INBRX-101, recombinant alpha-1 antitrypsin for AATD.
Sanofi continued INBRX-101 development targeting rare disease market served only by plasma-derived therapies with supply constraints.
Sanofi reported efdoralprin alfa (SAR447537, fka INBRX-101) met the primary endpoint (functional AAT trough at steady state, p<0.0001) and key secondary endpoints at Q3W and Q4W dosing vs weekly plasma-derived therapy in the 97-patient ElevAATe Phase 2 study; Sanofi to engage global regulators on next steps. Validates the AATD thesis.
INBRX-101 targets underserved AATD market with recombinant alternative to plasma-derived therapy. Mid-stage development; $2.2B reflects rare disease premium.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Inhibrx Inc. (this deal) | 2024 | $2.2B | 70 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2024 deals · Sanofi SA deals · Rare Disease deals